Emergent BioSolutions (EBS) Non-Current Deferred Tax Liability (2013 - 2026)

Emergent BioSolutions has reported Non-Current Deferred Tax Liability for 11 years, with the latest figure at $35.4 million in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 23.87% year-over-year to $35.4 million in Q2 2026; TTM through Jun 2026 was $35.4 million, a 23.87% decrease from a year earlier, with the FY2025 full-year figure at $37.8 million, down 22.7% from the prior year.
• Non-Current Deferred Tax Liability was $35.4 million for Q2 2026 at Emergent BioSolutions, up from $33.3 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $125.4 million in Q4 2022, with the low at $33.3 million in Q1 2026.
• Average Non-Current Deferred Tax Liability over 5 years is $59.2 million, with a median of $50.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability jumped 114.91% in 2022, then tumbled 53.99% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $125.4 million in 2022, then slumped by 53.03% to $58.9 million in 2023, then dropped by 16.98% to $48.9 million in 2024, then slipped by 22.7% to $37.8 million in 2025, then dropped by 6.35% to $35.4 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $35.4 million (Q2 2026), $33.3 million (Q1 2026), and $37.8 million (Q4 2025), per Business Quant data.